HomeCompareSNPHF vs KMB

SNPHF vs KMB: Dividend Comparison 2026

SNPHF yields 2.31% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNPHF wins by $2.3K in total portfolio value· pulled ahead in Year 10
10 years
SNPHF
SNPHF
● Live price
2.31%
Share price
$10.99
Annual div
$0.25
5Y div CAGR
33.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.2K
Annual income
$8,450.71
Full SNPHF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — SNPHF vs KMB

📍 SNPHF pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNPHFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNPHF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNPHF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNPHF
Annual income on $10K today (after 15% tax)
$196.32/yr
After 10yr DRIP, annual income (after tax)
$7,183.10/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, SNPHF beats the other by $2,744.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNPHF + KMB for your $10,000?

SNPHF: 50%KMB: 50%
100% KMB50/50100% SNPHF
Portfolio after 10yr
$47.0K
Annual income
$6,836.52/yr
Blended yield
14.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

SNPHF
No analyst data
Altman Z
5.0
Piotroski
7/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNPHF buys
0
KMB buys
0
No recent congressional trades found for SNPHF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNPHFKMB
Forward yield2.31%5.25%
Annual dividend / share$0.25$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.6%17%
Portfolio after 10y$48.2K$45.9K
Annual income after 10y$8,450.71$5,222.34
Total dividends collected$24.8K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SNPHF vs KMB ($10,000, DRIP)

YearSNPHF PortfolioSNPHF Income/yrKMB PortfolioKMB Income/yrGap
1$11,009$308.57$11,314$614.45$305.00KMB
2$12,203$424.14$12,867$760.19$664.00KMB
3$13,645$587.05$14,713$945.27$1.1KKMB
4$15,419$819.56$16,924$1,181.90$1.5KKMB
5$17,655$1,156.39$19,596$1,486.64$1.9KKMB
6$20,544$1,653.23$22,850$1,882.16$2.3KKMB
7$24,384$2,402.01$26,849$2,399.80$2.5KKMB
8$29,651$3,559.74$31,812$3,083.36$2.2KKMB
9$37,131$5,404.68$38,033$3,994.72$902.00KMB
10← crossover$48,181$8,450.71$45,918$5,222.34+$2.3KSNPHF

SNPHF vs KMB: Complete Analysis 2026

SNPHFStock

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Full SNPHF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this SNPHF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNPHF vs SCHDSNPHF vs JEPISNPHF vs OSNPHF vs KOSNPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.